In the context of the phase III Breast Cancer International Research Group (BCIRG) 006 trial investigating combination chemotherapy with or without trastuzumab, it has been observed that lack of PTEN expression by IHC is related to a poor prognosis in HER2-amplified tumors [17]. The gene discussed is PTEN; the disease is breast cancer.